Clinical trials
Hepatocellular Cancer clinical trials
Below are recruiting hepatocellular cancer clinical trials, each written for real people, not researchers. We’re tracking 202 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07376707RecruitingPhase 1
Study of TGI-5 alone or with nivolumab for advanced solid tumors
This trial tests a new drug called TGI-5, either by itself or combined with another drug (nivolumab), for people with advanced cancer that hasn't responded to standard treatments. It's looking for patients with certain types of solid tumors, especially colorectal, melanoma, lung, or others that have stopped responding to therapy.
ShanghaiAges 18 years+ - NCT06636435RecruitingPhase 1
Study of CBA-1205 for advanced cancers including liver, melanoma, and pediatric cancer
This trial tests a new drug called CBA-1205 for people with advanced solid tumors, liver cancer, melanoma, or certain childhood cancers that have not responded to standard treatments. The drug targets a protein called DLK1 found on some cancer cells.
Kashiwa, ChibaAges 2 years+ - NCT07223424RecruitingPhase 2
Patient preference study: shot vs infusion for immunotherapy
This study compares two ways to take immunotherapy drugs (nivolumab or pembrolizumab): as a shot under the skin (subcutaneous) versus an infusion into a vein (intravenous). It looks at which method patients prefer and is for people with certain advanced cancers where these drugs are already approved.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07174570RecruitingPhase 2
Celecoxib with immunotherapy for advanced liver cancer
This trial tests a combination of two immunotherapy drugs (durvalumab and tremelimumab) plus a pain reliever (celecoxib) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this three-drug combination works better than standard treatments.
Atlanta, GeorgiaAges 18 years+ - NCT04510129Recruiting
Cancer biospecimen collection study for immunotherapy patients
This study collects samples (like tissue biopsies and imaging information) from people with certain cancers who are starting anti–PD-1/PD-L1 immunotherapy. It helps researchers gather material to study how these treatments work.
San Francisco, CaliforniaAges 18 years+ - NCT05168163RecruitingPhase 2
Atezolizumab plus targeted drug for advanced liver cancer
This Phase 2 study tests whether atezolizumab combined with a multi-targeted (“multi-kinase”) inhibitor can treat advanced liver cancer that cannot be cured with surgery or local procedures. It focuses on people whose cancer has already grown despite a first-line treatment using atezolizumab plus bevacizumab.
Scottsdale, ArizonaAges 18 years+ - NCT04204850RecruitingPhase 2
Cabozantinib for liver cancer that returns after liver transplant
This trial studies cabozantinib, a cancer medicine, for liver cancer that has come back after a liver transplant. It’s for people whose cancer can’t be cured with more surgery or local procedures, to see if the treatment can help control the disease.
Toronto, OntarioAges 18 years+ - NCT06345508Recruiting
Finding liver cancer early with ultrasound
This study tests a new ultrasound technique to catch liver cancer sooner. If you have regular imaging checks for liver cancer or are getting an MRI for a liver spot, you may be able to join.
Montreal, QuebecAges 18 years+ - NCT06084234RecruitingPhase 4
National liver cancer screening trial
This trial is testing a new way to screen for liver cancer in people with cirrhosis or chronic hepatitis B. It aims to find cancer earlier so it can be treated more effectively.
Los Angeles, CaliforniaAges 18–85 - NCT07419841RecruitingPhase 1
A study of CTX-10726 for certain advanced cancers
This trial tests a new drug called CTX-10726 in people with advanced kidney, liver, stomach, or uterine cancer that has not responded to standard treatments. The goal is to see if the drug is safe and tolerable.
Omaha, NebraskaAges 18 years+ - NCT06540508Enrolling by invitation
TACE with targeted immunotherapy for advanced liver cancer
This study looks at whether combining a liver-directed procedure called TACE with tiragolumab and targeted therapy works better for people with unresectable liver cancer that has not spread too far. Researchers will use blood and tissue tests to see how well the treatment works.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06242470RecruitingPhase 1
Study of MGC026 for advanced solid tumors
This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.
Los Angeles, CaliforniaAges 18 years+ - NCT04348838Recruiting
Study of people newly diagnosed with liver cancer in France
This study follows people with hepatocellular carcinoma (HCC), a type of liver cancer, to learn how it changes over time. It may help improve understanding of which patients benefit from different care approaches.
AmiensAges 18 years+ - NCT06326502RecruitingPhase 1
A study of ETN101 for advanced liver cancer
This trial tests an experimental oral drug (ETN101) for adults with advanced liver cancer (hepatocellular carcinoma) that has gotten worse after standard treatments or can't be treated with standard therapy. It aims to see if the drug is safe and effective.
SeoulAges 19–65 - NCT06342414Recruiting
Blood test to tell apart two types of liver cancer
This study uses a blood test (called a liquid biopsy) to help doctors tell the difference between two common types of liver cancer: hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). If you have been diagnosed with one of these cancers and have a blood sample taken before starting curative treatment, this study may help improve diagnosis and care.
Duarte, CaliforniaAges 18 years+ - NCT07594964RecruitingPhase 1
Safety Study of XH001 Injection for High-Risk Recurrent Solid Tumors
This early-stage trial tests a new injection called XH001 as an additional treatment after surgery for patients with high-risk cancers that have come back. The goal is to check if it's safe and whether it helps prevent the cancer from returning again.
BeijingAges 18–70 - NCT06179602Recruiting
Study of thermal ablation for liver tumors
This study follows patients who are having a procedure called thermal ablation to treat liver tumors. It aims to learn more about how well the procedure works and how safe it is.
LeidenAges 18–110 - NCT06553885RecruitingPhase 2
Study of enfortumab vedotin for advanced colorectal or liver cancer
This trial tests a drug called enfortumab vedotin for people whose colorectal or liver cancer has spread or cannot be removed and has stopped responding to or is intolerant to standard treatments. The drug is given through a vein and works by targeting cancer cells.
Tampa, FloridaAges 18 years+ - NCT07070518RecruitingPhase 1/Phase 2
Study of GV20-0251 for advanced solid tumors
This trial tests a new study drug, GV20-0251, for people with advanced solid tumors that no longer respond to standard therapies. It aims to see if the drug can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05208762RecruitingPhase 1
PD-L1 antibody drug study for advanced lung and head/neck cancers
This Phase 1 trial tests a new experimental drug (PF-08046054/SGN-PDL1V) in people with advanced solid tumors that have not responded to standard treatment or can’t use it. It is designed to see how the drug works and how safe it is, with a focus on tumors that have PD-L1 seen on prior lab testing.
Birmingham, AlabamaAges 18 years+ - NCT05257590RecruitingPhase 2
CVM-1118 plus nivolumab for advanced liver cancer
This Phase 2 trial tests whether CVM-1118 given with nivolumab can help people with advanced, unresectable hepatocellular carcinoma (a type of liver cancer) that can’t be cured with surgery. It’s for patients whose cancer has worsened after earlier cancer medicines or treatments.
Kaohsiung CityAges 18 years+ - NCT06114082RecruitingPhase 2
Comparing two chemo drugs for liver cancer TACE
This study compares two chemotherapy drugs, idarubicin and doxorubicin, given during a liver cancer treatment called TACE (a procedure that delivers chemo directly to the tumor). It is for people with early-stage liver cancer who have not been treated before.
SeoulAges 19 years+ - NCT07405086RecruitingPhase 4
Morning vs. afternoon immunotherapy for advanced solid tumors
This trial compares giving immunotherapy in the morning versus the afternoon to see if timing affects how well it works. It is for people with certain types of advanced or metastatic solid tumors who have not had this treatment before.
Portland, OregonAges 18 years+ - NCT07042919RecruitingPhase 1/Phase 2
Zanzalintinib for advanced liver cancer after prior treatment
This trial tests a new drug called zanzalintinib for people with advanced liver cancer (HCC) that can't be treated with surgery. You may join if your cancer has gotten worse after at least one prior treatment, or you couldn't tolerate that treatment.
Chicago, IllinoisAges 18 years+
Hear when a new Hepatocellular Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatocellular cancer?
- Yes. Clin2 currently lists 202 recruiting hepatocellular cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatocellular cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatocellular cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.